Clinical Evidence Pivotal Studies and Randomized Controlled Trial Evidence Description of Studies Study 023 was a phase III, open-label trial with a 14-week, randomized, double-blind, placebo-controlled period followed by a 52-week, open-label period that aimed to evaluate the efficacy and safety of setmelanotide (1 mg to 3 mg daily by subcutaneous [SC] injection) in patients aged greater than or equal to 6 years with BBS or Alstrm syndrome (AS) and obesity
IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells
If youre diagnosed with melanoma: Make an appointment to see a healthcare provider or dermatologist as soon as you notice: Your provider will check your skin, take a biopsy (if needed), make a diagnosis and discuss treatment
Glyoxalase 1 copy number variation in patients with well differentiated gastro-entero-pancreatic neuroendocrine tumours (GEP-NET) Oncotarget
Its important to start with a lower dose and gradually increase it
One additional Phase III trial is assessing whether Survodutide can help overweight or obese individuals, as well as diagnosed or suspected MASH patients, reduce liver fat and lose weight
